Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy.
The incidence of arterial embolism (AE) and pulmonary embolism (PE) during treatment with oral anticoagulants (OA) or without OA therapy was studied in 38 patients with dilated cardiomyopathy (DCMP). AE/PE occurred in 17 patients (44.7%) before initiation of OA treatment. The severity of DCMP was a risk factor for AE/PE, but not the presence of atrial fibrillation or intracardial thrombi. No AE/PE episodes occurred during the period of OA therapy. No major bleeding complications were seen, probably due to the moderate intensity of OA therapy (therapeutic range 5-15% Thrombotest [TT], 2.1-4.8 International Normalized Ratio [INR], median TT value 11%, median INR 2.6). Recurrence of AE was observed in 4 of 5 patients in whom treatment with OA had been discontinued.
D015110:4-Hydroxycoumarins / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001158:Arteries; D002311:Cardiomyopathy, Dilated / Q000097:blood / Q000150:complications*; D004617:Embolism / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000009:adverse effects / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D012306:Risk
D015110:4-Hydroxycoumarins; D010644:Phenprocoumon